PR Newswire: news distribution, targeting and monitoring
 

Promising New Drug and Other Trends To Double Smoking Cessation and Addiction Treatments Market by 2010

 
    NEW YORK, May 30 /PRNewswire/ -- With the advent of a possible new
 blockbuster drug and greater reimbursement levels for the treatment of
 nicotine, alcohol, and drug addictions, global sales of smoking cessation
 and addiction treatments are expected to rise from revenues of little over
 $1.1 billion in 2005 to more than $2.3 billion in 2010, according to
 Smoking Cessation and Addiction Treatments: A World Market Analysis, a new
 study released today from Kalorama Information.
     Nicotine is clearly the most abused drug worldwide, with over 1.4
 billion incidences, including 50 million users in the U.S. alone. Smoking
 cessation has continually become a particular focus of global health
 agencies, and the increasing high awareness of effective smoking cessation
 products have helped to drive market growth.
     The market now dominated by GlaxoSmithKline with its Zyban smoking
 cessation treatment, and Schering-Plough / Reckitt Benckiser with their
 Suboxone/Subetex substance abuse treatment, is primed for a dramatic change
 as Pfizer moves into smoking cessation.
     "We believe Pfizer's Chantix will acquire the largest share of the
 market, overtaking GlaxoSmithKline in smoking cessation, and leading all
 addiction treatments based on the superior effectiveness of Pfizer's
 product in clinical studies," notes Melissa Elder, the report's author. "To
 a more limited extent, new drugs in alcohol and substance abuse treatments
 will also change those markets."
     Smoking Cessation and Addiction Treatments: A World Market Analysis
 includes world incidence and data for nicotine addiction, drug addiction,
 and alcohol abuse; current and forecasted revenues through 2010; current
 and forecasted market share with consideration of new players in the
 market; reviews of current products and new products in the pipeline; and
 key trends driving pharmaceutical treatments for smoking cessation and
 drug/alcohol addiction. It can be purchased directly from Kalorama
 Information by visiting
 http://www.kaloramainformation.com/Smoking-Cessation-Addiction-1460041. It
 is also available at MarketResearch.com.
     About Kalorama Information
     Kalorama Information, a division of MarketResearch.com, supplies the
 latest in independent market research on medical markets. For more
 information, contact Tom Ehart at 240-747-3014 or
 tehart@marketresearch.com, or visit www.KaloramaInformation.com.
     Contact:
     Tom Ehart
     MarketResearch.com
     240-747-3014
     tehart@marketresearch.com
 
 

SOURCE Kalorama Information
Back to top

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

Featured Video

 
  • Print
  • Email
  •   RSS
  • Share it 
  • Blog it 
  • Blog Search 

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Free Investing Newsletter from Investor Uprising!

Learn to navigate the world's financial system and profit from leading companies.  


Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All The Glitters: The Ultimate Gold Report".

Advanced Search
Search
  
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire